Generate Biomedicines, Inc.
NASDAQ:GENBAsset Management
+$0.13 today
- Market cap
- $1.34B
- Beta
- 0.19
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$4.06
Volume 1.05M
Average 0.55M
GENB Debt Repayment
Cash used to repay borrowings during the period.
Generate Biomedicines, Inc.NASDAQ: GENB
Debt Repayment · Q1 FY2026 · quarter ended Mar 2026
Debt repayment of -$1.12M in Q1 FY2026
Q1 FY2026 debt repayment was -$1.12M.
Context
- Debt repayment amounted to 25.6% of revenue in FY2025, down 28.8 pp from a year earlier.
Sources:Cash FlowText generated from reported figures; not investment advice.
Debt Repayment history
USD · from the cash flow
- Latest · FY2025
- (8.16M) USD
- Year-over-year change
- +26.6%
| Period | Period end | Debt Repayment | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (8.16M) | +26.6% |
| FY2024 | 2024-12-31 | (11.12M) | — |
Debt Repayment vs competitors
How GENB compares with its peers on the latest reported figures
- GENB's FY2025 debt repayment of $8.16M is the 3rd largest of the 5 companies compared; the peer median is $8.86M.
- Its year-over-year change of -26.6% is the 3rd highest of 4, against a peer median of -25.0%.
- Debt repayment amounts to 25.6% of revenue for GENB, versus a peer median of 90.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $74.99M | -25.0% | — | 5768.6% | |
| LTM Sep 2026 | $17.72M | -29.4% | — | 26.1% | |
GENBGenerate Biomedicines, Inc. | FY2025 | $8.16M | -26.6% | — | 25.6% |
| LTM Mar 2026 | $2.85M | -20.2% | — | 155.1% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding GENB) | $8.86M | -25.0% | — | 90.6% | |
Competitors are the stored peer set for GENB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Net Income | (181.38M) | (222.97M) |
| Depreciation & Amortization | 15.35M | 13.18M |
| Deferred Income Tax | 0 | 0 |
| Stock-Based Compensation | 19.47M | 20.58M |
| Change in Working Capital | 28.12M | (14.62M) |
| Accounts Receivables | (213K) | 308K |
| Inventory | 0 | 0 |
| Accounts Payables | 3.5M | (2.13M) |
| Other Working Capital | 24.83M | (12.79M) |
| Other Non-Cash Items | 702K | 3.21M |
| Operating Cash Flow | (117.75M) | (200.62M) |
| Capital Expenditures | (3.45M) | (3.51M) |
| Acquisitions (Net) | 0 | 0 |
| Purchases of Investments | (282.98M) | (164.73M) |
| Sales of Investments | 228.69M | 285.01M |
| Other Investing Activities | 10K | 0 |
| Investing Cash Flow | (57.73M) | 116.77M |
| Debt Repayment | (11.12M) | (8.16M) |
| Common Stock Issued | 0 | 0 |
| Common Stock Repurchased | 0 | 0 |
| Dividends Paid | 0 | 0 |
| Other Financing Activities | 6.13M | 14.25M |
| Financing Cash Flow | 91.33M | 28.06M |
| Effect of Forex Changes | 0 | 0 |
| Net Change in Cash | (84.15M) | (55.79M) |
| Free Cash Flow | (121.2M) | (204.13M) |
Generate Biomedicines, Inc.
NASDAQ:GENB
Intrinsic Alpha fair value
Locked
Current Price
$10.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.